(MedPage Today) — ORLANDO — A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable residual disease (MRD)-negative responses in the first four patients with relapsed/refractory multiple myeloma…
Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118951
Author :
Publish date : 2025-12-11 15:47:00
Copyright for syndicated content belongs to the linked Source.
